Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
The Fundamentals of Chemotherapy Immunotherapy Administration Renewal Course builds on the lessons you received in the Fundamentals of Chemotherapy Immunotherapy Administration Course to ensure that your chemotherapy and immunotherapy knowledge remains current and you’re continuing to progress as an experienced oncology RN.
The ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal Course will guide you through four strategically planned case studies to ensure that your chemotherapy and immunotherapy knowledge stays current and you’re continuing to progress as an experienced oncology RN.
Learn about the process, risks, monitoring needs, and potential side effects of CAR T-cell therapy treatment of hematologic malignancies, with an emphasis on patient and family education. An interactive scenario and supporting resources reinforce learning.
Level of evidence scales rank evidence by the research methodology that would answer the clinical question with the least amount of error and provide the most reliable findings. The purpose of this additional information is to provide the learner with a guide to prioritize evidence. The higher a methodology ranks, the more confidence clinicians can have that the intervention will produce the same outcomes in similar patients.
As the use of CAR T-Cell therapy grows, understanding the events involved, the adverse events associated with this therapy and evidence-based management strategies is critical. Use this resource to enhance your understanding of the process behind CAR T-Cell therapy and nursing considerations associated with the treatment.
Refresh your knowledge on immunotherapy, an antineoplastic treatment modality. This card reviews immunotherapy, providing examples as well as its benefits, limitations, and targets.
Follow a nurse through assessment and early interventions to better understand cytokine release syndrome, an adverse reaction associated with Car T-Cell therapy.